In a regulatory filing Friday, Agenus Inc (NASDAQ:AGEN) revealed Bristol Myers Squibb & Co (NYSE:BMY) terminated a license, development, and commercialization agreement forged in 2021. The company said that as part of a broader strategic realignment of their development pipeline, which involves other licensed products, Bristol Myers Squibb is returning AGEN1777, a TIGIT bispecific antibody, to Agenus and voluntarily terminating the BMS License Agreement, effective as of January 26, 2025. Related: Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity. Most recently, Roche Holdings AG's (OTC:RHHBY) TIGIT drug, tiragolumab, failed in Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer ...